Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer

Phase 1 Completed 48 enrolled National Cancer Institute (NCI)

NaSingle-groupOpen-labelTreatment

Summary

Phase I trial to study the effectiveness of vaccine therapy with or without sargramostim in treating patients who have advanced or metastatic cancer. Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may make tumor cells more sensitive to the vaccine and may kill more tumor cells

Timeline

Start: 2001-11
Primary completion: 2005-11
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Recombinant Fowlpox GM-CSF Vaccine Adjuvant	Vaccine	—	Intramuscular
Subject	recombinant fowlpox-CEA(6D)/TRICOM vaccine	Vaccine	—	Intramuscular
Subject	sargramostim	Protein / enzyme biologic	—	Subcutaneous

Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer

Summary

Timeline

Drugs

Indications